US 12,419,861 B2
Method for preventing and/or treating chronic traumatic encephalopathy-i
Robert Vink, Mylor (AU)
Assigned to Eustralis Pharmaceuticals Limited (trading as PresSura Neuro), Melbourne (AU)
Filed by EUSTRALIS PHARMACEUTICALS LIMITED (trading as Pressura Neuro), Melbourne (AU)
Filed on Mar. 29, 2022, as Appl. No. 17/707,784.
Application 17/707,784 is a continuation of application No. 16/945,271, filed on Jul. 31, 2020, granted, now 11,426,384.
Application 16/945,271 is a continuation of application No. 14/902,239, granted, now 10,729,677, previously published as PCT/AU2014/050107, filed on Jul. 2, 2014.
Claims priority of application No. 2013902455 (AU), filed on Jul. 2, 2013.
Prior Publication US 2022/0218663 A1, Jul. 14, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 25/28 (2006.01); A61K 31/405 (2006.01); A61K 31/496 (2006.01)
CPC A61K 31/405 (2013.01) [A61K 31/496 (2013.01); A61P 25/28 (2018.01)] 6 Claims
 
1. A method of inhibiting tau hyperphosphorylation in a base of sulci in a subject who has suffered multiple concussive events, comprising administering to the subject a pharmaceutically acceptable composition consisting essentially of an NK1 receptor antagonist at a dose of from 0.25 mg/kg to 25 mg/kg effective to inhibit tau hyperphosphorylation in the subject, wherein the dose of NK1 receptor antagonist is effective to maintain NK1 receptor antagonist blood concentration in a therapeutic range for at least 3 days and inhibit tau hyperphosphorylation in the base of the sulci.